GlassScriptPhysician profile
James W Dean
NPI 1346270493
$3,897.92
in general payments reported to CMS, 2019-2025
43 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $506 · 2021: $1,007 · 2022: $468 · 2023: $141 · 2024: $383 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $626.44 | 2023-2025 | |
| Lilly USA, LLC | $508.34 | 2020-2025 | Amyvid, Kisunla |
| Novartis Pharmaceuticals Corporation | $306.46 | 2019-2025 | |
| Biogen, INC. | $236.43 | 2019-2022 | |
| Amgen INC. | $198.51 | 2019-2023 | Aimovig |
| Abbvie INC. | $166.79 | 2021-2022 | |
| Livanova USA, INC. | $164.39 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $154.40 | 2019-2021 | |
| Allergan, INC. | $121.68 | 2019-2020 | |
| Lundbeck LLC | $107.72 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $104.34 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $103.23 | 2022-2023 | Ultomiris |
| Corium, LLC | $99.61 | 2022-2023 | Adlarity |
| Emd Serono, INC. | $88.67 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $80.92 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.